Lonza Invests CHF 20 million to Expand API Development and Manufacturing Facility in Nansha, China

New investments will include three 1,000L GMP trains with an overall 12m3 of reactor volume

01-Jul-2021 - Switzerland

Lonza today announced new investments in GMP laboratories and mid-scale manufacturing assets at its API manufacturing center in Nansha, China. The investments, totaling over CHF 20 million, will allow Lonza to provide a smoother transition from small-scale to large-scale manufacturing for customers while maintaining Lonza’s global quality and regulatory standards.

Lonza

Lonza Invests CHF 20 million to Expand API Development and Manufacturing Facility in Nansha, China

The expansion will include six 1,000L small molecule reactors, four 1,500L vessels, and isolation equipment providing mid-scale capacity to bridge between early-phase and late-phase production. The additional GMP laboratories will be able to develop and manufacture highly potent API (HPAPI) under GMP standards.

Lonza’s Nansha site is fully integrated within the company’s global manufacturing network. Scientists and engineers based in Nansha focus on API development and manufacturing for customers around the globe. The Lonza team also contains regulatory specialists with experience working with Chinese regulators throughout the drug development and scale-up process. Approximately 250 employees work at Lonza’s Nansha site; this expansion is expected to create around 70 new positions.

The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances